Free Trial

Heatwurx (PCSA) Competitors

Heatwurx logo
$0.21 +0.00 (+0.38%)
Closing price 04:00 PM Eastern
Extended Trading
$0.21 -0.01 (-2.82%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PCSA vs. LSB, GLYC, GNPX, TLPH, DWTX, ADXN, AEON, APRE, KPRX, and IMNN

Should you be buying Heatwurx stock or one of its competitors? The main competitors of Heatwurx include LakeShore Biopharma (LSB), GlycoMimetics (GLYC), Genprex (GNPX), Talphera (TLPH), Dogwood Therapeutics (DWTX), Addex Therapeutics (ADXN), AEON Biopharma (AEON), Aprea Therapeutics (APRE), Kiora Pharmaceuticals (KPRX), and Imunon (IMNN). These companies are all part of the "pharmaceutical products" industry.

Heatwurx vs. Its Competitors

Heatwurx (NASDAQ:PCSA) and LakeShore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

Heatwurx has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, LakeShore Biopharma has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500.

Heatwurx has higher earnings, but lower revenue than LakeShore Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HeatwurxN/AN/A-$11.85M-$3.08-0.07
LakeShore Biopharma$80.82MN/A-$61.09MN/AN/A

LakeShore Biopharma's return on equity of 0.00% beat Heatwurx's return on equity.

Company Net Margins Return on Equity Return on Assets
HeatwurxN/A -319.56% -232.40%
LakeShore Biopharma N/A N/A N/A

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 52.6% of LakeShore Biopharma shares are owned by institutional investors. 9.6% of Heatwurx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Heatwurx presently has a consensus target price of $2.00, indicating a potential upside of 838.97%. Given Heatwurx's stronger consensus rating and higher probable upside, analysts plainly believe Heatwurx is more favorable than LakeShore Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heatwurx
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
LakeShore Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Heatwurx's average media sentiment score of 1.89 beat LakeShore Biopharma's score of 1.25 indicating that Heatwurx is being referred to more favorably in the media.

Company Overall Sentiment
Heatwurx Very Positive
LakeShore Biopharma Positive

Summary

Heatwurx beats LakeShore Biopharma on 8 of the 11 factors compared between the two stocks.

Get Heatwurx News Delivered to You Automatically

Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PCSA vs. The Competition

MetricHeatwurxMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.52M$2.46B$5.54B$9.41B
Dividend YieldN/A1.80%3.75%4.03%
P/E RatioN/A4.4521.0120.09
Price / SalesN/A709.89433.8199.01
Price / CashN/A164.7736.1658.27
Price / Book0.465.008.125.65
Net Income-$11.85M$30.99M$3.25B$257.91M
7 Day Performance-5.84%1.69%0.97%2.09%
1 Month Performance-11.98%9.20%7.36%11.13%
1 Year Performance-87.01%-1.25%31.31%18.40%

Heatwurx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PCSA
Heatwurx
3.048 of 5 stars
$0.21
+0.4%
$2.00
+839.0%
-87.6%$2.52MN/A0.0020
LSB
LakeShore Biopharma
0.8199 of 5 stars
$1.11
+2.8%
N/A-76.3%$10.05M$80.82M0.00773Positive News
Gap Down
GLYC
GlycoMimetics
N/A$0.16
-6.6%
N/A-99.5%$10.00M$10K-0.3450High Trading Volume
GNPX
Genprex
1.3581 of 5 stars
$0.30
+8.3%
N/A-85.8%$9.95MN/A0.0020
TLPH
Talphera
2.4028 of 5 stars
$0.47
-8.9%
$5.00
+955.1%
-53.3%$9.72M$27K-1.0519Positive News
High Trading Volume
DWTX
Dogwood Therapeutics
1.717 of 5 stars
$5.08
+6.7%
$10.00
+96.9%
N/A$9.71MN/A-0.285
ADXN
Addex Therapeutics
2.4098 of 5 stars
$9.02
+2.2%
$30.00
+232.4%
+2.4%$9.57M$460K-26.5430News Coverage
Positive News
AEON
AEON Biopharma
2.4476 of 5 stars
$0.83
-0.7%
$360.00
+43,039.6%
-99.6%$9.43MN/A4.645Gap Down
APRE
Aprea Therapeutics
2.9391 of 5 stars
$1.70
-1.7%
$15.50
+811.8%
-58.1%$9.40M$1.50M-0.727Positive News
Gap Up
KPRX
Kiora Pharmaceuticals
3.2944 of 5 stars
$3.08
+2.7%
$10.00
+224.7%
-28.0%$9.38MN/A-1.0610
IMNN
Imunon
2.1308 of 5 stars
$0.52
-14.1%
$15.50
+2,880.8%
-58.4%$9.12MN/A-0.3830Positive News

Related Companies and Tools


This page (NASDAQ:PCSA) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners